For management of a suspected drug overdose, contact your regional Poison Control Centre.
There is no human data available on overdosage with XALACOM (latanoprost and timolol maleate).
Symptoms of systemic timolol overdosage are: bradycardia, hypotension, bronchospasm, and cardiac arrest. If such symptoms occur, treatment should be symptomatic and supportive. Studies have shown that timolol is not readily dialyzable.
Apart from ocular irritation and conjunctival or episcleral hyperemia, the ocular effects of latanoprost administered at high doses are not known. Intravenous infusion of up to 3 mcg/kg in healthy volunteers induced no symptoms, but a dose of 5.5-10 mcg/kg caused nausea, abdominal pain, dizziness, fatigue, hot flashes, and sweating. These events were mild to moderate in severity and resolved without treatment within 4 hours after terminating the infusion.
In monkeys latanoprost has been infused intravenously to doses up to 500 mcg/kg without major effects on the cardiovascular system. Intravenous administration of latanoprost in monkeys has been associated with transient bronchoconstriction.
If overdose with XALACOM occurs, treatment should be symptomatic.
If XALACOM is accidentally ingested the following information may be useful: One bottle contains 125 mcg latanoprost and 12.5 mg timolol. Both timolol and latanoprost are extensively metabolized in the liver. In fact, more than 90% of latanoprost is metabolized during the first pass through the liver.